Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring
© 2023, The American College of Clinical Pharmacology..
Hypokalemia and hyponatremia are common but easily ignored adverse events in treatment with voriconazole (VCZ) that can lead to serious consequences. We intend to investigate the incidence of VCZ-induced hypokalemia and hyponatremia and their risk factors based on real-world data. A prospective study was conducted. A total of 272 patients with 414 VCZ plasma trough concentrations (C0) and VCZ N-oxide concentrations (CN) were included. The incidence of hypokalemia was 18.0% (48/266). A total of 81.2% (39/48) of patients developed hypokalemia within 14 days, whereas 56.2% (27/48) of patients developed hypokalemia within 1 week. The proportion of female patients in the hypokalemia group was higher than that in the nonhypokalemia group, as was the proportion of patients receiving intravenous VCZ. In the multivariate analysis, the independent risk factors for hypokalemia were sex, combined use of antibiotics, and VCZ CN/C0. The incidence of hyponatremia was 7.9% (21/266). The proportion of patients over 47 years of age in the hyponatremia group was 71.4% (15/21). The number of days of VCZ use in the hyponatremia group was greater than that in the nonhyponatremia group. A total of 47.6% (10/21) of patients in the hyponatremia group had supratherapeutic VCZ C0 (>5.0 µg/mL). In conclusion, hypokalemia is more likely to occur in females, in patients receiving intravenous VCZ, and in patients with the combined use of antibiotics. Hyponatremia is more likely to occur in patients older than 47 years who have been using VCZ for a long time and have higher VCZ C0 values.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
---|---|
Enthalten in: |
Journal of clinical pharmacology - 64(2024), 4 vom: 01. Apr., Seite 461-468 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cheng, Lin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-Bacterial Agents |
---|
Anmerkungen: |
Date Completed 28.03.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jcph.2381 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364019220 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364019220 | ||
003 | DE-627 | ||
005 | 20240422231948.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jcph.2381 |2 doi | |
028 | 5 | 2 | |a pubmed24n1383.xml |
035 | |a (DE-627)NLM364019220 | ||
035 | |a (NLM)37910022 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cheng, Lin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.03.2024 | ||
500 | |a Date Revised 22.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023, The American College of Clinical Pharmacology. | ||
520 | |a Hypokalemia and hyponatremia are common but easily ignored adverse events in treatment with voriconazole (VCZ) that can lead to serious consequences. We intend to investigate the incidence of VCZ-induced hypokalemia and hyponatremia and their risk factors based on real-world data. A prospective study was conducted. A total of 272 patients with 414 VCZ plasma trough concentrations (C0) and VCZ N-oxide concentrations (CN) were included. The incidence of hypokalemia was 18.0% (48/266). A total of 81.2% (39/48) of patients developed hypokalemia within 14 days, whereas 56.2% (27/48) of patients developed hypokalemia within 1 week. The proportion of female patients in the hypokalemia group was higher than that in the nonhypokalemia group, as was the proportion of patients receiving intravenous VCZ. In the multivariate analysis, the independent risk factors for hypokalemia were sex, combined use of antibiotics, and VCZ CN/C0. The incidence of hyponatremia was 7.9% (21/266). The proportion of patients over 47 years of age in the hyponatremia group was 71.4% (15/21). The number of days of VCZ use in the hyponatremia group was greater than that in the nonhyponatremia group. A total of 47.6% (10/21) of patients in the hyponatremia group had supratherapeutic VCZ C0 (>5.0 µg/mL). In conclusion, hypokalemia is more likely to occur in females, in patients receiving intravenous VCZ, and in patients with the combined use of antibiotics. Hyponatremia is more likely to occur in patients older than 47 years who have been using VCZ for a long time and have higher VCZ C0 values | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a hypokalemia | |
650 | 4 | |a hyponatremia | |
650 | 4 | |a therapeutic drug monitoring | |
650 | 4 | |a voriconazole | |
650 | 4 | |a voriconazole N‐oxide | |
650 | 7 | |a Voriconazole |2 NLM | |
650 | 7 | |a JFU09I87TR |2 NLM | |
650 | 7 | |a Antifungal Agents |2 NLM | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
700 | 1 | |a Liu, Zhirui |e verfasserin |4 aut | |
700 | 1 | |a Yu, Mingjie |e verfasserin |4 aut | |
700 | 1 | |a Lin, Ling |e verfasserin |4 aut | |
700 | 1 | |a Xiong, Lirong |e verfasserin |4 aut | |
700 | 1 | |a Dai, Qing |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g 64(2024), 4 vom: 01. Apr., Seite 461-468 |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
773 | 1 | 8 | |g volume:64 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:461-468 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.2381 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 64 |j 2024 |e 4 |b 01 |c 04 |h 461-468 |